This study is a single-center, prospective, nonrandom, single-arm trial.
Aged 18-65 years old, including the boundary value, no gender restriction;
MGFA clinical class II-IV;
Anti-acetylcholine-receptor antibody (AChR-Ab) shows positive;
Willing to participate in the study, understand and sign the informed consent form (ICF).
Received IVMP, IVIG, or TPE within the 2 months before the current visit;
Unable to cooperate in completing the MG-ADL, or QMG, or Quantitative QMG questionnaire.
Judged by a senior clinician to have any of the following: 1)Severe or chronic urinary-tract infection; 2)History of recurrent infections; 3)Previous allergy to any human-derived biologic drug; 4)Depression, suicidal ideation, or other psychiatric disorder;
Patients with active infection, such as herpes zoster, HIV, active tuberculosis, or active hepatitis.